Evidence map›Paper›PMID 30872112›Full record

ArticleThe Lancet. Child & adolescent health2019

MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.

Cristina Pellegrini, Francesca Botta, Daniela Massi, Claudia Martorelli, Fabio Facchetti, Sara Gandini, Patrick Maisonneuve, Marie-Françoise Avril, Florence Demenais, Brigitte Bressac-de Paillerets and 45 more

Open access · bronzeAbstract read
In one paragraph

Article in The Lancet. Child & adolescent health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

55 authors at 20 institutions in 11 countries.

Cristina PellegriniDepartment of Dermatology and Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Francesca BottaDivision of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
Daniela MassiDivision of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
Claudia MartorelliDepartment of Dermatology and Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Fabio FacchettiPathology Section, Department of Molecular and Translational Medicine, Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Sara GandiniMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Patrick MaisonneuveDivision of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Milan, Italy.
Marie-Françoise AvrilAPHP, Dermatology Department, Hôpital Cochin and Paris Descartes University, Paris, France.
Florence DemenaisGenetic Variation and Human Diseases Unit (UMR-946), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Brigitte Bressac-de PailleretsDepartment of Biopathology and INSERM, University of Paris-Saclay, Villejuif, France.
Veronica HoiomDepartment of Oncology and Pathology, Cancer Centre, Karolinska Institutet, Stockholm, Sweden.
Anne E CustSydney School of Public Health and Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
Hoda Anton-CulverDepartment of Epidemiology, University of California, Irvine, CA, USA.
Stephen B GruberUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Richard P GallagherBritish Columbia Cancer and Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Loraine MarrettCancer Care Ontario, Toronto, ON, Canada.
Roberto ZanettiPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
Terence DwyerGeorge Institute for Global Health, Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, UK.
Nancy E ThomasLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Colin B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marianne BerwickDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Susana PuigMelanoma Unit, Dermatology Department, Hospital Clinic Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, and CIBER de Enfermedades Raras, Barcelona, Spain.
Miriam PotronyMelanoma Unit, Dermatology Department, Hospital Clinic Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, and CIBER de Enfermedades Raras, Barcelona, Spain.
Eduardo NagoreDepartment of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
Paola GhiorzoDepartment of Internal Medicine and Medical Specialties, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy.
Chiara MeninDiagnostic Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Ausilia Maria ManganoniDepartment of Dermatology, Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Monica RodolfoDepartment of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Sonia BrugnaraOncology Unit, Santa Chiara Hospital, Trento, Italy.
Emanuela PassoniDepartment of Pathophysiology and Transplantation, University of Milan, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Lidija Kandolf SekulovicDepartment of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
Federica BaldiniDivision of Melanoma, Sarcoma and Rare Cancer, European Institute of Oncology IRCCS, Milan, Italy.
Gabriella GuidaDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy.
Alexandros Stratigos1st Department of Dermatology, Andreas Sygros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Fezal OzdemirDepartment of Dermatology, Faculty of Medicine, University of Ege, Izmir, Turkey.
Fabrizio AyalaMelanoma Unit, Cancer Immunotherapy and Innovative Therapies, IRCCS Istituto Nazionale dei Tumori, Fondazione G Pascale, Napoli, Italia.
Ricardo Fernandez-de-MisaDermatology Service, University Hospital Nuestra Senora de Candelaria, Santa Cruz de Tenerife, Spain.
Pietro QuaglinoDermatologic Clinic, Department of Medical Sciences, University of Torino, Turin, Italy.
Gloria RibasDepartment of Medical Oncology and Haematology, Fundación Investigación Clínico de Valencia, INCLIVA Instituto de Investigación Sanitaria, Valencia, Spain.
Antonella RomaniniUS Ambulatori Melanomi, Sarcomi e Tumori Rari, UO Oncologia Medica 1, Azienda Ospedaliero-Universitaria Santa Chiara, Pisa, Italy.
Emilia MiglianoPlastic Surgery, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Ignazio StanganelliSkin Cancer Unit, IRCCS Scientific Institute of Romagna for the Study and Treatment of Cancer and University of Parma, Meldola, Italy.
Peter A KanetskyDepartment of Cancer Epidemiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Maria Antonietta PizzichettaUniversity of Trieste, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy.
Jose Carlos García-BorrónDepartment of Biochemistry, Molecular Biology, and Immunology, University of Murcia and IMIB-Arrixaca, Murcia, Spain.
Hongmei NanDepartment of Epidemiology, Richard M Fairbanks School of Public Health, Melvin & Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA.
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Julian LittleSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Julia Newton-BishopSection of Epidemiology and Biostatistics, Institute of Medical Research at St James', University of Leeds, Leeds, UK.
Francesco SeraDepartment of Public Health, Environments and Society, London School of Hygiene & Tropical Medicine, London, UK.
Maria Concetta FargnoliDepartment of Dermatology and Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Sara RaimondiMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: sara.raimondi@ieo.it.
IMI Study Group
GEM Study Group
M-SKIP Study Group
University of L'Aquila · ITCentro de Investigación Biomédica en Red · ESEuropean Institute of Oncology · ITUniversity of New Mexico · USAzienda Ospedaliera Universitaria Pisana · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITInserm · FRIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Oncologico Veneto · ITMoffitt Cancer Center · USNational Institutes of Health · USPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Bari Aldo Moro · ITUniversity of British Columbia · CAUniversity of Florence · ITUniversity of Leeds · GBUniversity of North Carolina at Chapel Hill · USCancer Care Ontario · CAEge University · TRFondazione IRCCS Istituto Nazionale dei Tumori · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage MelanomaP01CA206980 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BERWICK, MARIANNE, THOMAS, NANCY E. · 2017 to 2022
$10.1M
Melanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4M
Solar Exposure and Melanoma SurvivalR01CA112524 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 2005 to 2009
$2.5M
Molecular Epidemiology of MelanomaR01CA092428 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KANETSKY, PETER A · 2002 to 2006
$2.3M
MELANOMA AND ALLELIC VARIATION IN THE MCIR GENEK07CA080700 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KANETSKY, PETER A · 2000 to 2005
$634k
Cancer Research UK 10589Cancer Research UK 19167NCI NIH HHS K07 CA080700NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA092428NCI NIH HHS R01 CA112243NCI NIH HHS R01 CA112524
6 · The paper itself

Abstract

backgroundGermline variants in the melanocortin 1 receptor gene (MC1R) might increase the risk of childhood and adolescent melanoma, but a clear conclusion is challenging because of the low number of studies and cases. We assessed the association of MC1R variants with childhood and adolescent melanoma in a large study comparing the prevalence of MC1R variants in child or adolescent patients with melanoma to that in adult patients with melanoma and in healthy adult controls.

methodsIn this retrospective pooled analysis, we used the M-SKIP Project, the Italian Melanoma Intergroup, and other European groups (with participants from Australia, Canada, France, Greece, Italy, the Netherlands, Serbia, Spain, Sweden, Turkey, and the USA) to assemble an international multicentre cohort. We gathered phenotypic and genetic data from children or adolescents diagnosed with sporadic single-primary cutaneous melanoma at age 20 years or younger, adult patients with sporadic single-primary cutaneous melanoma diagnosed at age 35 years or older, and healthy adult individuals as controls. We calculated odds ratios (ORs) for childhood and adolescent melanoma associated with MC1R variants by multivariable logistic regression. Subgroup analysis was done for children aged 18 or younger and 14 years or younger.

findingsWe analysed data from 233 young patients, 932 adult patients, and 932 healthy adult controls. Children and adolescents had higher odds of carrying MC1R r variants than did adult patients (OR 1·54, 95% CI 1·02-2·33), including when analysis was restricted to patients aged 18 years or younger (1·80, 1·06-3·07). All investigated variants, except Arg160Trp, tended, to varying degrees, to have higher frequencies in young patients than in adult patients, with significantly higher frequencies found for Val60Leu (OR 1·60, 95% CI 1·05-2·44; p=0·04) and Asp294His (2·15, 1·05-4·40; p=0·04). Compared with those of healthy controls, young patients with melanoma had significantly higher frequencies of any MC1R variants.

interpretationOur pooled analysis of MC1R genetic data of young patients with melanoma showed that MC1R r variants were more prevalent in childhood and adolescent melanoma than in adult melanoma, especially in patients aged 18 years or younger. Our findings support the role of MC1R in childhood and adolescent melanoma susceptibility, with a potential clinical relevance for developing early melanoma detection and preventive strategies.

fundingSPD-Pilot/Project-Award-2015; AIRC-MFAG-11831.

Indexed as

Germ-Line MutationAdolescentAdultAgedBiomarkers, TumorCase-Control StudiesChildFemaleGenetic Predisposition to DiseaseHumansLogistic ModelsMaleMelanomaMiddle AgedOdds RatioPolymorphism, GeneticBiomarkers, TumorMC1R protein, humanReceptor, Melanocortin, Type 1

Identifiers

PMID30872112
PMCPMC6942319
OpenAlexW2920946574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.